Close
FINDING CURES TOGETHER<sup>SM</sup>

​​AAC​R Science Series at the FDA

The AACR Science Series at the FDA sessions began in July 2012. This series brings scientific leaders to the FDA campus to present cutting-edge advances in cancer biology to FDA scientific review staff and to foster the development of relationships between FDA reviewers and external scientific experts. Since January 2013, the AACR has been offering CME credits for these sessions.​

Epigenetics, Dec. 7, 2015

Stephen B. Baylin, MD, professor of oncology and medicine, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland

Charles W.M. Roberts, MD, PhD, director and executive vice president, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Nashville, Tennessee

​Highlights of the AACR Annual Meeting 2015, July 27, 2015

Carlos L. Arteaga, MD, associate director for Clinical Research; leader, Breast Cancer Research Program; director, Breast Cancer Research Program; and director, Center for Cancer Targeted Therapies at Vanderbilt-Ingram Cancer Center, Nashville, Tennessee and AACR president (2014-2015)

Lewis C. Cantley, PhD, Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, New York, New York

Novel Approaches to Rational Drug Design, Dec. 12, 2014

Nathanael Gray, PhD, professor of biological chemistry and molecular pharmacology at Harvard Medical School and cancer biology at Dana Farber Cancer Institute, Boston, Massachusetts

Lawrence Marnett, PhD, university professor, the director of the A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Mary Geddes Stahlman professor of cancer research, and professor of biochemistry, chemistry, and pharmacology, Vanderbilt University, Nashville, Tennessee

Highlights of the AACR Annual Meeting 2014, July 21, 2014

Charles L. Sawyers, MD, chairman, Human Oncology and Pathogenesis Program; Marie-Josee and Henry R. Kravis chair at Memorial Sloan Kettering Cancer Center and AACR president (2013-2014)

Scott W. Lowe, PhD, chair of the Cancer Biology and Genetics Program and the Geoffrey Beene Cancer Research Center and Howard Hughes Medical Institute investigator at Memorial Sloan Kettering Cancer Center  

Novel Non-Invasive Techniques to Detect and Monitor Tumors, March 10, 2014

Victor E. Velculescu, MD, PhD, professor of oncology, director of cancer genetics, Ludwig Center at Johns Hopkins and co-director of cancer biology, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland 

Daniel A. Haber, MD, PhD, director, Massachusetts General Hospital Cancer Center and the Isselbacher/Schwartz professor of oncology at Harvard Medical School, Boston, Massachusetts     

Targeting Metabolic Pathways in Hematologic Malignancies and Solid Tumors, November 4, 2013

Kenneth C. Anderson, MD, PhD (hon), Kraft Family professor of medicine, Department of Medicine, Harvard Medical School; physician, oncology, Brigham And Women's Hospital; medical director, Kraft Family Blood Center, Dana-Farber Cancer Institute; and director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts

Lewis C. Cantley, PhD, director, Cancer Center, Weill Cornell Medical College of Cornell University, New York, New York

Highlights of the AACR Annual Meeting 2013, July 29, 2013

Frank P. McCormick, PhD, FRS, director, UCSF Helen Diller Family Comprehensive Cancer Center; associate dean, UCSF School of Medicine; David A. Wood distinguished professorship of tumor biology and cancer research, San Francisco, California; and immediate past president of the AACR and chair of the AACR’s Regulatory Science and Policy Subcommittee

Jeffrey A. Engelman, MD, PhD, director, Center for Thoracic Cancers at Massachusetts General Hospital Cancer Center and associate professor of medicine at Harvard Medical School, Boston, Massachusetts

Rational Strategies for Developing BRAF Inhibitors: Rational Combinations; Overcoming Resistance, Jan. 14, 2013

Frank P. McCormick, PhD, FRS, director, UCSF Helen Diller Family Comprehensive Cancer Center; associate dean, UCSF School of Medicine; David A. Wood distinguished professorship of tumor biology and cancer research, San Francisco, California; and immediate past president of the AACR and chair of the AACR’s Regulatory Science and Policy Subcommittee

Gideon E. Bollag, PhD, CEO, Research, Plexxikon Inc., Berkeley, California

Immunotherapies, Oct. 1, 2012

James P. Allison, PhD, professor and chair,  The University of Texas MD Anderson Cancer Center; Department of Immunology in the Division of Basic Science Research, deputy director, David H. Koch Center for Applied Research in Genitourinary Cancers, Department of Genitourinary Medical Oncology and Research, Houston, Texas; and investigator, Howard Hughes Medical Institute

David L. Porter, MD, Jodi Fisher Horowitz professor in leukemia care excellence and director, Blood and Marrow Transplantation, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Highlights of the AACR Annual Meeting 2012, July 23, 2012

Frank P. McCormick, PhD, FRS, director, UCSF Helen Diller Family Comprehensive Cancer Center; associate dean, UCSF School of Medicine; David A. Wood distinguished professorship of tumor biology and cancer research, San Francisco, California; and immediate past president of the AACR; and chair of the AACR’s Regulatory Science and Policy Subcommittee

Benjamin G. Neel, PhD, MD, director of research of the Princess Margaret Cancer Centre, University Health Network, Toronto, Canada